See ratings and reviews when you sign up for an account.

Special Investigation (All Case Survey) in Patients With Juvenile Idiopathic Arthritis

This study is currently Recruiting

August 2011 By Abbott

First Recieved on August 5, 2011

Last Updated on August 5, 2011

Sponsor: Abbott
Information provided by: Abbott
Identifier: NCT01412021


This study of Humira will be conducted to clarify the following with regard to the treatment of juvenile idiopathic arthritis affecting multiple joints with this drug: - Unknown adverse drug reactions (especially important adverse drug reactions) - Incidence and conditions of occurrence of adverse reactions in the clinical setting - Factors that may affect the safety and effectiveness of Humira

Study Type: Observational
Study Design: Observational Model: Cohort, Time Perspective: Prospective


Ages Eligible for Study:N/A
Genders Eligible for Study:Both
Accepts Healthy Volunteers:No

Inclusion Criteria: - All patients with Juvenile idiopathic arthritis who are not responding well to conventional therapy and receive Humira will be enrolled in the survey. Exclusion Criteria: - Contraindications according to the Package Insert - Patients who have serious infections - Patients who have tuberculosis - Patients with a history of hypersensitivity to any ingredient of Humira - Patients who have demyelinating disease or with a history of demyelinating disease - Patients who have congestive cardiac failure


  • Investigator: Toshiro Maeda - Study Director - Abbott Japan Co.,Ltd


  • Site Ref # / Investigator 60666

    Okayama, Japan

  • Site Ref # / Investigator 60665

    Osaka, Japan

  • Site Ref # / Investigator 49892

    Tokyo, Japan

Disclaimer: The list and ratings above are for informational purposes only, and is intended to supplement, not substitute for, the expertise and judgment of your physician, pharmacist or other healthcare professional. The goal of the information is to provide you with a comprehensive view of all available treatments, but should not be construed to indicate that use of any one treatment is safe, appropriate, or effective for you. Decisions about use of a new treatment, or about a change in your current treatment plan, should be in consultation with your doctor or other healthcare professional.